Apricus Biosciences Inc. (NASDAQ:APRI) has been given an average rating of “Hold” by the five ratings firms that are currently covering the stock. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $2.23.
Separately, Zacks Investment Research cut Apricus Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, July 26th.
A hedge fund recently raised its stake in Apricus Biosciences stock. Healthcare Value Capital LLC boosted its position in shares of Apricus Biosciences Inc. (NASDAQ:APRI) by 83.3% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 440,000 shares of the company’s stock after buying an additional 200,000 shares during the period. Apricus Biosciences comprises approximately 0.4% of Healthcare Value Capital LLC’s investment portfolio, making the stock its 20th largest position. Healthcare Value Capital LLC owned about 0.71% of Apricus Biosciences worth $256,000 at the end of the most recent quarter. 23.83% of the stock is currently owned by institutional investors and hedge funds.
Shares of Apricus Biosciences (NASDAQ:APRI) opened at 0.355 on Tuesday. The firm’s market capitalization is $23.55 million. Apricus Biosciences has a 1-year low of $0.28 and a 1-year high of $1.66. The stock has a 50 day moving average of $0.36 and a 200-day moving average of $0.44.
Apricus Biosciences (NASDAQ:APRI) last released its earnings results on Thursday, August 4th. The company reported ($0.05) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.03. During the same period in the prior year, the firm earned ($0.10) EPS. On average, equities analysts expect that Apricus Biosciences will post ($0.17) earnings per share for the current year.